In agreement with the previous study, BRAF mutation has been reported in 30-80% of PTC, and also in AC which develops from pre-existing PTC, but is never detected in follicular carcinoma or benign nodules (Lee et al., 2007). This evidence concerns the gene BRAF and thyroid gland follicular carcinoma.